HANGZHOU TIGERMED CONSULTING CO., LTD Hangzhou Tigermed Consulting Co., Ltd Share Price OTC Markets
Equities
HNGZY
US41044T1088
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.2 USD | -4.55% |
|
-.--% | -.--% |
| 06-18 | Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes | CI |
| 06-14 | Tigermed Consulting Assures Normal Operations Amid Share Price Fluctuations | MT |
| Sales 2024 * | 8.11B 1.12B 88.18B | Sales 2025 * | 9.01B 1.24B 98.04B | Capitalization | 40.63B 5.6B 442B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.05B 282M 22.31B | Net income 2025 * | 2.47B 340M 26.84B | EV / Sales 2024 * | 4.2 x |
| Net cash position 2024 * | 7.3B 1.01B 79.45B | Net cash position 2025 * | 7.8B 1.07B 84.85B | EV / Sales 2025 * | 3.64 x |
| P/E ratio 2024 * |
21.4
x | P/E ratio 2025 * |
17.7
x | Employees | - |
| Yield 2024 * |
1% | Yield 2025 * |
1.18% | Free-Float | 69.68% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -4.55% |
1 year
4.20
4.40
3 years
4.2012.75
5 years
4.2012.75
10 years
4.2012.75
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 31/12/04 |
Hao Wu
PSD | President | 56 | 31/12/19 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 31/12/04 |
Bing Hui Zhang
CHM | Chairman | 61 | 27/04/20 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows:
- provision of clinical trial services and related technological services (51.8%);
- provision of clinical research consulting services (48.2%).
China accounts for 46% of sales.
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
50.36
CNY
Average target price
74.23
CNY
Spread / Average Target
+47.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.14% | 51.51B | |
| -7.43% | 39.03B | |
| +35.88% | 38.91B | |
| -10.62% | 26.68B | |
| +11.63% | 26.13B | |
| -17.77% | 19.91B | |
| +40.52% | 13.71B | |
| +30.70% | 12.38B | |
| -3.41% | 11.74B |
- Stock Market
- Equities
- 300347 Stock
- HNGZY Stock
